Sanofi American Depositary Receipt (SNY)
Itepekimab Failure A Setback For Sanofi And Regeneron
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials
Sanofi and Regeneron said that drug candidate Itepekimab didn't meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
Sanofi to Buy Vigil Neuroscience for About $470 Million
Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer's disease to the French pharmaceutical company's pipeline.
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research & Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Conference Call Participants Richard Vosser - JPMorgan Luisa Hector - Berenberg Colleen Garvey - Guggenheim Ben Jackson - Jefferies Peter Verdult - BNP Exane Jo Walton - UBS Graham Parry - BofA James Quigley - Goldman Sachs Florent Cespedes - Bernstein Sarita Kapila - Morgan Stanley Simon Baker - Redburn Thomas Kudsk Larsen Hello everyone. This is Thomas Kudsk Larsen from the Sanofi IR team.
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Why You Shouldn't Bet Against Sanofi (SNY) Stock
Sanofi (SNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
